Introduction {#s1}
============

The Organ of Corti contains mechanosensory hair cells (HC) and specialized supporting cells (SC) that are required for the transduction of sound ([@bib48]). The frequency spectrum of sound stimuli is tonotopically represented along the length of the mammalian cochlea ([@bib13]). In mouse, the cochlea begins to grow from the ventral otic vesicle at embryonic day 11.5 (E11.5) and continues to grow and coil, forming approximately one and a half turns by birth. During its development, the length of the cochlea is limited by the number of progenitors that give rise to sensory HCs and SCs, and is further regulated through a process of convergent extension ([@bib8]; [@bib29]; [@bib47]; [@bib48]). In mouse, sensory progenitors exit the cell cycle by E14.5 and begin to differentiate into HCs and SCs. Thus, the size of the progenitor population at this stage of development is the ultimate determinant of the size of the adult cochlea. Progenitor number is determined by proliferation, the timing of differentiation, and in some cases by aberrant cell death. Previous studies indicate that sensory progenitor growth requires mesenchymal signals ([@bib35]; [@bib28]; [@bib4], [@bib5][@bib5]), however, the identity and source of the factors that control this activity are not known.

Fibroblast Growth Factors (FGFs) have several stage-specific functions during inner ear development. FGF3 and FGF10 signal from hindbrain and head mesenchyme, respectively, to the overlying ectoderm to induce formation of the otic placode and vesicle ([@bib45]). Later in development, FGF20 regulates differentiation of outer hair cells (OHC) and SCs, termed the lateral compartment of the cochlea ([@bib18]). Phenotypic similarities with mice lacking *Fgfr1* in the entire otic epithelium suggest that FGF20 signals directly to FGFR1, serving as a permissive factor for differentiation ([@bib37]; [@bib16]; [@bib18]). FGF9 signaling regulates structural components of the vestibular system, but alone has no effect on cochlear development ([@bib38]). During postmitotic stages, FGF8 signaling from the inner hair cell (IHC) to FGFR3 in SCs regulates pillar cell differentiation ([@bib10]; [@bib30]; [@bib20]).

Here, we identify another critical stage in inner ear development that requires FGF signaling. We show that *Fgf9*, expressed in the non-sensory epithelium, and *Fgf20*, expressed in the sensory epithelium, regulate the number of cochlear progenitors and the ultimate length of the cochlea through signaling to mesenchymal FGFRs. We find that in vivo FGF9/20 signaling to mesenchymal FGFR1 and FGFR2 is required for sensory progenitor proliferation and that mesenchymal FGFR signaling is sufficient to promote sensory progenitor proliferation and extend the length of the cochlear duct. In addition, we show that prosensory epithelial FGFR1 and FGF20 independently is required for differentiation of outer HCs and SCs.

Results {#s2}
=======

*Fgf9* and *Fgf20* are expressed in the developing cochlea {#s2-1}
----------------------------------------------------------

In a prior study, we showed that *Fgf20* is required between E13.5--14.5 for differentiation of cochlear OHCs and SCs in the organ of Corti ([@bib18]). However, *Fgf20* is expressed in a portion of the otic vesicle sensory epithelium much earlier in development, beginning at E10.5 ([@bib18]), but analysis of mice lacking *Fgf20* did not reveal any function for *Fgf20* at this stage of development. Since there are many examples of FGFs functioning redundantly during development, we hypothesized that redundancy could account for the lack of a phenotype in *Fgf20* null inner ears between E10.5 and 12.5. *Fgf9* is closely related to *Fgf20* ([@bib51]; [@bib19]), and is also expressed in the otic epithelium at E10.5--12.5 ([@bib38]); however, *Fgf9*^*−/−*^ mice have normal cochlear development and normal patterning of the organ of Corti ([@bib38]).

We first examined the expression domain of *Fgf9* relative to Sox2-expressing sensory progenitors (and *Fgf20*) using a new *Fgf9-*βGal reporter allele (*Fgf9*^*lacZ*^) in which a splice acceptor-lacZ gene was inserted into the first intron of *Fgf9* ([@bib42]). At E10.5, βGal activity was detected in the otic vesicle epithelium ([Figure 1A](#fig1){ref-type="fig"}). Co-staining of βGal and Sox2 at E11.5 showed no overlap, indicating that *Fgf9* is expressed in the non-sensory epithelium of the otic vesicle ([Figure 1B](#fig1){ref-type="fig"}). Taken together with previous *Fgf20* expression analysis at this stage ([@bib18], [Figure 1C](#fig1){ref-type="fig"}), *Fgf9* and *Fgf20* are both expressed in the otic vesicle, but in non-overlapping domains in the otic epithelium ([Figure 1D](#fig1){ref-type="fig"}).10.7554/eLife.05921.003Figure 1.*Fgf9* and *Fgf20* are expressed in distinct regions of the otic vesicle.(**A**) βGal activity in an *Fgf9*^*lacZ/+*^ embryo at E10.5 visualized with xGal staining. (**B**, **C**) βGal (red) and Sox2 (green) co-immunostaining showing that *Fgf9* (**B**) is expressed in Sox2^-^ non-sensory epithelium and *Fgf20* (**C**) is expressed in Sox2^+^ sensory epithelium at E11.5. (**D**) Schematic diagram of FGF9, FGF20, and Sox2 immunostaining showing that FGF9 and FGF20 are expressed in distinct domains in the otic vesicle. ov, otic vesicle, scale bars, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.003](10.7554/eLife.05921.003)

*Fgf9* and *Fgf20* regulate cochlear length and *Fgf20*, not *Fgf9*, is required for lateral compartment differentiation and patterning {#s2-2}
---------------------------------------------------------------------------------------------------------------------------------------

To determine whether *Fgf9* and *Fgf20* could have a redundant role in cochlear development, *Fgf9;Fgf20* double knockout cochleae were analyzed at E18.5 by staining with phalloidin and with an antibody to p75 to identify sensory HCs and pillar cells, respectively ([Figure 2A--C](#fig2){ref-type="fig"}). Control embryos (*Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^) showed a normal pattern of three rows of OHCs and one row of IHCs throughout the cochlear duct ([Figure 2A--C](#fig2){ref-type="fig"}). *Fgf9*^*−/−*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/+*^ cochleae showed the same wild type HC pattern as the double heterozygous controls ([Figure 2A--C](#fig2){ref-type="fig"}). *Fgf20*^*lacZ/lacZ*^ and *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ cochleae showed patches of sensory HCs and gaps ([Figure 2A--C](#fig2){ref-type="fig"})^^ ([@bib18]). *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ cochleae also showed a similar patterning phenotype to *Fgf20*^*lacZ/lacZ*^ mice ([Figure 2A--D](#fig2){ref-type="fig"}). The density (number of cells per 100 μm) of OHCs in *Fgf9*^*−/−*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/+*^ cochleae was similar to double heterozygous controls ([Figure 2E](#fig2){ref-type="fig"}). However, the densities of OHCs in *Fgf20*^*lacZ/lacZ*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ cochleae were similar to each other (ANOVA, p \> 0.1), and significantly (ANOVA, p \< 0.0001) decreased compared to double heterozygous controls ([Figure 2E](#fig2){ref-type="fig"}). Densities of IHCs were comparable in all genotypes ([Figure 2E](#fig2){ref-type="fig"}). To analyze SCs, cochleae were immunostained for Prox1 and Sox2 ([Figure 2D](#fig2){ref-type="fig"}). In double heterozygous control cochleae, 5 rows of Prox1^+^ SCs overlapped with Sox2 staining ([Figure 2D](#fig2){ref-type="fig"}). *Fgf9*^*−/−*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/+*^ cochleae showed a similar pattern ([Figure 2D](#fig2){ref-type="fig"}). In contrast, *Fgf20*^*lacZ/lacZ*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ cochleae showed patches of SCs separated by gaps of Sox2^+^, Prox1^−^ cells ([Figure 2D](#fig2){ref-type="fig"}). The density of SCs in *Fgf9*^*−/−*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/+*^ was comparable (ANOVA, p \> 0.5) to double heterozygous control ([Figure 2F](#fig2){ref-type="fig"}). The density of SCs in *Fgf20*^*lacZ/lacZ*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ were similar to each other (ANOVA, p \> 0.3) and significantly (ANOVA, p \< 0.0001) decreased compared to double heterozygous controls ([Figure 2F](#fig2){ref-type="fig"}).10.7554/eLife.05921.004Figure 2.*Fgf9* and *Fgf20* regulate cochlear length.(**A**, **B**) Phalloidin (**A**) and p75 immunostaining (**B**) of E18.5 whole cochlea showing hair cells (HCs) (phalloidin) and pillar cells (p75) in the cochlear duct of *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^*, Fgf9*^*−/−*^, *Fgf20*^*lacZ/lacZ*^, *Fgf9*^*−/−*^*;Fgf20*^*lacZ/+*^*, Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ and, *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ embryos. (**C**) Phalloidin (green) and p75 immunostaining (red) showing the orientation of HCs, pillar cells, and gaps in the sensory epithelium. (**D**) Prox1 (green) and Sox2 (red) co-immunostaining showing supporting cells (SCs) (yellow, Prox1 and Sox2) and undifferentiated sensory progenitors (red, Sox2). (**E**--**G**) Measurement of HC number (**E**), SC number (**F**), and length of cochleae (**G**) of E18.5 embryos. Scale bars, **A**, 500 μm; **C**, 100 μm. For statistical analysis, all samples were compared with *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^ double heterozygous controls. \*p \< 0.001. Sample numbers (n) are indicated in data bars.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.004](10.7554/eLife.05921.004)

One of the striking differences among *Fgf9;Fgf20* compound mutants was cochlear length. The length of *Fgf9*^*−/−*^ and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/+*^ cochleae was comparable (ANOVA, p \> 0.1) to that of double heterozygous controls ([Figure 2G](#fig2){ref-type="fig"}), whereas the length of *Fgf20*^*lacZ/lacZ*^ and *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ cochleae was 16% and 18% shorter than double heterozygous controls (p \< 0.05 and p \< 0.001), respectively, and the length of *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ cochleae was reduced by 58% compared to controls (p \< 0.001) ([Figure 2G](#fig2){ref-type="fig"}). In addition, *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ double knockout cochleae were 49% and 51% of the length of *Fgf20*^*lacZ/lacZ*^ and *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ cochleae (p \< 0.001), respectively ([Figure 2G](#fig2){ref-type="fig"}). These data identify a redundant role for *Fgf9* and *Fgf20* to attain the proper cochlear length, while *Fgf20*, alone, primarily regulates cochlear patterning and differentiation.

*Fgf9* and *Fgf20* regulate sensory progenitor cells proliferation {#s2-3}
------------------------------------------------------------------

We hypothesized that the overall length of the cochlear duct would correlate with the size of the postmitotic prosensory domain. In mouse, cochlear sensory progenitors exit the cell cycle beginning at E12.5 in the apex and progressing towards the base by E14.5 ([@bib24]). E14.5 cochleae were dissected and immunostained for Sox2 ([Figure 3A](#fig3){ref-type="fig"}), which marks the lineage of cells that will become HCs and SCs ([@bib22]). The Sox2^+^ prosensory domain of double heterozygous control and *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ inner ears were similar ([Figure 3A](#fig3){ref-type="fig"}). However, the Sox2^+^ prosensory domain of *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ inner ears were clearly smaller than that of double heterozygous control or *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ cochleae ([Figure 3A](#fig3){ref-type="fig"}). Immunostaining of histological sections of E14.5 inner ears showed that the Sox2^+^ prosensory domain was less compact in *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ inner ears compared to double heterozygous control and inner ears with one wild type allele of *Fgf9* ([Figure 3B](#fig3){ref-type="fig"}). Immunostaining for p27^kip1^ (Cdkn1b) showed a very similar pattern to that of Sox2, with more diffuse cells in the prosensory domain of E14.5 inner ears of *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ mice ([Figure 3C](#fig3){ref-type="fig"}). Jag1, which marks the medial prosensory cells that will give rise to IHCs, inner SCs, and Kölliker\'s organ ([@bib32]; [@bib2]), showed a similar expression pattern across all three genotypes, indicating that the medial compartment of the cochlea was correctly specified ([Figure 3D](#fig3){ref-type="fig"}).10.7554/eLife.05921.005Figure 3.*Fgf9* and *Fgf20* are required for sensory progenitor proliferation.(**A**) Sox2 immunostaining of whole E14.5 cochlea to identify the progenitor domain (arrows). (**B**--**D**) Sox2 (**B**), p27 (**C**), and Jag1 (**D**) immunostaining of E14.5 *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^, and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ embryo sections. Boxed regions of the cochlear duct are magnified below each image and were chosen in regions where the sections perpendicularly transect the cochlear duct. (**E**, **F**) Sox2 and phospho-Histone H3 (pHH3) co-immunostaining of E11.5 (**E**) and E12.5 (**F**) *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ and, *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ embryo sections. (**G**, **H**) Measurement of Sox2^+^ sensory progenitor proliferation at E11.5 (**G**) and E12.5 (**H**). All samples were compared with *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^ double heterozygous controls. \*p \< 0.01, \*\*p \< 0.001. Sample numbers (n) are indicated in data bars. See also [Figure 3---figure supplements 1, 2](#fig3s1 fig3s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.005](10.7554/eLife.05921.005)10.7554/eLife.05921.006Figure 3---figure supplement 1.Proliferation of sensory progenitors.(**A**) Sox2 and EdU staining of E11.5 *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^, and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ embryo sections. (**B**) Measurement of Sox2^+^ sensory progenitor proliferation at E11.5. All samples were compared with *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^ double heterozygous controls. \*p \< 0.01. ns, not significant. Sample numbers (n) are indicated in data bars.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.006](10.7554/eLife.05921.006)10.7554/eLife.05921.007Figure 3---figure supplement 2.*Fgf9* and *Fgf20* loss do not cause premature cell cycle exit.(**A**--**C**) p27 (green) and Sox2 (red) co-immunostaining of E12.5 *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^ (**A**), *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ (**B**), and *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ (**C**) embryo sections.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.007](10.7554/eLife.05921.007)

To determine whether the decreased size of the *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ prosensory domain resulted from changes in cell proliferation and/or cell death, histological sections of E11.5 and E12.5 otic vesicles were immunostained for Sox2 and phospho-Histone H3 (pHH3) ([Figure 3E,F](#fig3){ref-type="fig"}), or activated Caspase-3 (aCasp3) (data not shown). Quantification of the number of pHH3^+^, Sox2^+^ sensory progenitors showed similar numbers (p \> 0.09 at E11.5 and p \> 0.2 at E12.5) in double heterozygous control and *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ cochleae ([Figure 3G,H](#fig3){ref-type="fig"}). However, proliferation of *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ cochlear epithelial cells was significantly decreased at E11.5 (p \< 0.001) and E12.5 (p \< 0.01) compared to double heterozygous controls ([Figure 3G,H](#fig3){ref-type="fig"}). In addition quantitation of cell proliferation using EdU labeling of E11.5 embryos showed similar results ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). No cell death (aCasp3^+^) was detected in any of the genotypes at E11.5 and E12.5 (data not shown).

Decreased sensory progenitor number could also result from premature cell cycle exit. p27^kip1^ is one of the cell cycle inhibitors that is expressed in sensory progenitors as they become postmitotic. Expression of p27^kip1^ begins at E12.5 in the apex of the cochlea and progresses towards the base ([@bib24]). By E14.5, the entire cochlear progenitor domain becomes p27^kip1^ positive. Expression of p27^kip1^ at E12.5 in the proximal cochlear duct was not detected in either control or *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ embryos suggesting that there is no premature cell cycle exit in mice lacking *Fgf9* and *Fgf20* ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

Epithelial *Fgfr1* but not *Fgfr2* is required for lateral compartment differentiation {#s2-4}
--------------------------------------------------------------------------------------

Next, we questioned which cell types are required for sensory progenitor proliferation and/or lateral compartment differentiation. Expression of both *Fgfr1* and *Fgfr2* have been reported in the otic epithelium and periotic mesenchyme between E10.5 and E12.5 ([@bib36], [@bib37], [@bib38]; [@bib33]). Epithelial *Fgfr1* has been conditionally inactivated in otic epithelium using *Foxg1*^*Cre*^, *Six1enh21*^*Cre*^, and *Emx2*^*Cre*^ ([@bib37]; [@bib33]). This results in a cochlear epithelium with reduced numbers of HCs, with OHC numbers being more severely affected than IHC numbers. In addition to the loss of differentiated HCs, a 40--50% decrease in cochlear length was reported when *Fgfr1* was inactivated with *Six1enh21*^*Cre*^, or *Emx2*^*Cre*^ ([@bib33]).

To directly compare cochlear phenotypes resulting from inactivation of *Fgfr1* in otic epithelium with embryos lacking *Fgf9* and *Fgf20*, we re-created and re-evaluated *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ mutant mice maintained on a 129X1/SvJ;C57BL/6J mixed genetic background. Quantification of the density of OHCs in *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ embryos demonstrated a significant (p \< 0.0001) decrease compared to controls (*Fgfr1*^*+/f*^*::Foxg1*^*Cre/+*^) ([Figure 4---figure supplement 1A,B,E](#fig4s1){ref-type="fig"}), while the density of IHCs was not changed (p \> 0.09). Furthermore, the length of *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ cochleae was only 9% shorter than control ([Figure 4---figure supplement 1A,B,F](#fig4s1){ref-type="fig"}), similar to what was observed in *Fgf20*^*lacZ/lacZ*^ embryos ([Figures 1B, 2G](#fig1 fig2){ref-type="fig"} and ref. [@bib18]). Whole mount Sox2 staining of E14.5 *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ cochleae was also comparable to control, indicating that the number of Sox2^+^ progenitors was not changed ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). In addition, proliferation of the *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ prosensory epithelium was comparable (p \> 0.6) to that of controls at E12.5 ([Figure 4---figure supplement 1D,G](#fig4s1){ref-type="fig"}).

Because *Fgfr2* often exhibits redundancy with *Fgfr1*, it is important to consider potential *Fgfr2* function in the inner ear prosensory epithelium. However, *Fgfr2* is required for formation of the otic vesicle and *Foxg1*^*Cre*^, which is active before and during the otic vesicle stage ([@bib17]), could not be used to investigate the role of *Fgfr2* at later stages of otic vesicle development. In addition, due to overall activity of *Foxg1*^*Cre*^ in the otic vesicle, cell type specificity of *Fgfr1* was still unknown. To study whether *Fgfr1* and/or *Fgfr2* function cell autonomously or non-cell autonomously in the *Fgf20*^+^ domain of the prosensory epithelium, we generated an *Fgf20*^*Cre*^ allele ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}) to allow conditional gene targeting of the *Fgf20* lineage. To assess Cre activity, *Fgf20*^*Cre/+*^*;ROSA*^*mTmG/+*^ mice were generated. Cre activity was detected at E10.5 in a subset of the Sox2^+^ prosensory domain, in a pattern identical to that of *Fgf20*^*lacZ*^ embryos ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). At P0, all of the components of the organ of Corti were positive for the *Fgf20*^*Cre/+*^*;ROSA*^*mTmG/+*^ lineage tracer, indicating that *Fgf20*^*Cre*^ is active in prosensory progenitors or their lineage ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}).

To identify potential roles for *Fgfr1* and *Fgfr2* in the prosensory epithelial lineage, we generated *Fgfr1* and *Fgfr2* single and double conditional mutant mice using the *Fgf20*^*Cre*^ allele. E18.5 embryos were harvested and stained with phalloidin and p75, to visualize cochlear morphology. The phenotype of *Fgfr1*^*−/f*^*::Fgf20*^*Cre/+*^(*Fgfr1*^*−/f*^*;Fgfr2*^*+/f*^*::Fgf20*^*Cre/+*^) cochleae was similar to that of *Fgf20*^*lacZ/lacZ*^*, Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^, and *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ cochleae ([Figures 2A--C, 4A--C](#fig2 fig4){ref-type="fig"}, [Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). In contrast, the pattern and morphology of *Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^(*Fgfr1*^*+/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^) cochleae was similar to control ([Figure 4A--C](#fig4){ref-type="fig"}) and *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ cochleae was comparable to *Fgfr1*^*−/f*^*::Fgf20*^*Cre/+*^ ([Figure 4A--C](#fig4){ref-type="fig"}). The density of OHCs in *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ was comparable to *Fgfr1*^*−/f*^*::Fgf20*^*Cre/+*^ (p \> 0.94) and significantly (p \< 0.001) decreased compared to control ([Figure 4F](#fig4){ref-type="fig"}). The density of OHCs of *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ embryos was comparable to control (p \> 0.6) ([Figure 4F](#fig4){ref-type="fig"}) and the density of IHCs in *Fgfr1*^*−/f*^*::Fgf20*^*Cre/+*^, *Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^, and *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ cochleae were indistinguishable (ANOVA, p \> 0.8) from that of controls ([Figure 4F](#fig4){ref-type="fig"}).10.7554/eLife.05921.008Figure 4.Cell-autonomous regulation of sensory progenitor differentiation requires epithelial *Fgfr1* but not *Fgfr2*.(**A**, **B**) Phalloidin (**A**) and p75 immunostaining (**B**) of E18.5 whole cochlea showing HCs (phalloidin) and pillar cells (p75) in the cochlear duct of control, *Fgfr1*^*−/f*^*::Fgf20*^*Cre/+*^ (*Fgfr1*^*−/f*^*;Fgfr2*^*+/f*^*::Fgf20*^*Cre/+*^), *Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ (*Fgfr1*^*+/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^) and, *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ embryos. (**C**) Phalloidin (green) and p75 immunostaining (red) showing the patterning of HCs and pillar cells in the cochlear duct. (**D**) Sox2 immunostaining of E14.5 whole cochlea to identify progenitor domains (arrows). (**E**) Sox2 and pHH3 co-immunostaining of E12.5 embryo sections. (**F**, **G**) Measurement of HC number (**F**) and length of cochleae (**G**) of E18.5 control embryos. (**H**) Measurement of Sox2^+^ sensory progenitor proliferation in E12.5 embryos. All samples were compared with controls. \*p \< 0.001; ns, not significant. Sample numbers (n) are indicated in data bars. See also [Figure 4---figure supplements 1, 2](#fig4s1 fig4s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.008](10.7554/eLife.05921.008)10.7554/eLife.05921.009Figure 4---figure supplement 1.Epithelial *Fgfr1* is required for lateral compartment differentiation and HC and SC patterning.(**A**, **B**) Phalloidin (**A**) and p75 immunostaining (**B**) of E18.5 whole cochlea showing HCs (phalloidin) and pillar cells (p75) in the cochlear duct of control and *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ embryos. (**C**) Sox2 immunostaining of E14.5 whole cochlea to identify progenitor domains (arrows). (**D**) Sox2 and pHH3 co-immunostaining of E12.5 embryo sections. (**E**, **F**) Measurement of HC number (**E**) and length of cochleae (**F**) of E18.5 control and *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ embryos. (**G**) Measurement of Sox2^+^ sensory progenitor proliferation in E12.5 cochleae. \*p \< 0.001 in **E** and \*p \< 0.01 in **F**. Sample numbers (n) are indicated in data bars.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.009](10.7554/eLife.05921.009)10.7554/eLife.05921.010Figure 4---figure supplement 2.Generation of an *Fgf20*^*Cre*^ knockin mouse line.(**A**) Schematic diagram showing targeting of the *Fgf20* genomic locus. Homologous recombination in mouse ES cells was used to insert a GFP:Cre (Cre) gene and neo selection cassette (flanked by Flip recombination target sequences, grey triangles) into exon 1 of *Fgf20*. F1 mice were bred to mice that express Flip recombinase in the germline to excise the neo selection cassette. Arrows indicate PCR primers used for genotyping. B, BamH1; X, Xho1. (**B**) *Fgf20*^*Cre/+*^*; ROSA26*^*mT/mG/+*^ (*ROSA*^*mT/mG/+*^) double transgenic mice showing the cumulative lineage of *Fgf20*^*Cre*^ expressing cells (green) in the Sox2^+^ prosensory domain (blue) at E10.5 and in HCs, SCs, and the greater epithelial ridge (GER) at P1. Recombination at the *ROSA26*^*mT/mG*^ locus silences membrane localized Tomato (mT) and activates membrane localized GFP (mG).**DOI:** [http://dx.doi.org/10.7554/eLife.05921.010](10.7554/eLife.05921.010)

The length of the cochleae from E18.5 *Fgfr1*^*−/f*^*::Fgf20*^*Cre/+*^ and *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ embryos was decreased by 19% and 25%, respectively, compared to controls (p \< 0.0001, [Figure 4G](#fig4){ref-type="fig"}). However, the length of the cochleae from *Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ was comparable (p \> 0.5) to controls. Together, these data, and those presented above, showed that epithelial *Fgfr1*, but not *Fgfr2*, is required for lateral compartment differentiation, and has a modest effect on cochlear duct length of a similar magnitude to the 10% reduction in cochlear length seen in *Fgf20*^*lacZ/lacZ*^ mice ([@bib18]). This reduction in cochlear length could be due to reduced numbers of progenitors or to other effects of FGFR1 signaling on cochlear duct elongation at later stages of development. Whole mount Sox2 staining at E14.5 of *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ cochleae showed a similarly sized sensory progenitor domain as compared to controls indicating that the Sox2^+^ progenitor population was not affected by inactivation of epithelial *Fgfr1* and *Fgfr2* ([Figure 4D](#fig4){ref-type="fig"}). In addition, proliferation of *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Fgf20*^*Cre/+*^ cochleae was comparable (p \> 0.5) to controls at E12.5 ([Figure 4E,H](#fig4){ref-type="fig"}).

Mesenchymal *Fgfr1* and *Fgfr2* regulate cochlear length but not lateral compartment differentiation {#s2-5}
----------------------------------------------------------------------------------------------------

We next asked whether mesenchymal FGFRs regulate cochlear length. *Twist2(Dermo1)*^*Cre*^ is widely expressed in mesenchymal cells ([@bib25]; [@bib44]). To determine whether *Twist2*^*Cre*^ is active in periotic mesenchyme during otic vesicle development, *Twist2*^*Cre/+*^*;ROSA26*^*lacZ/+*^ embryos were stained for lacZ activity at E9.5 and E10.5. lacZ activity was observed in all of the mesenchyme surrounding the unstained otic epithelium at both developmental time points ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). *Twist2*^*Cre*^ was then used to inactivate *Fgfr1* and *Fgfr2* from mesenchymal cells. Cochleae were dissected from E18.5 embryos and stained with phalloidin and p75. All genotypes showed normal sensory HC and SC patterning, with one row of IHCs and three rows of OHCs ([Figure 5A--C](#fig5){ref-type="fig"}). The linear density of IHCs and OHCs was comparable (ANOVA, p \> 0.2, p \> 0.8, respectively) among all genotypes ([Figure 5F](#fig5){ref-type="fig"}). However, the length of the cochleae of *Fgfr1*^*−/f*^*::Twist2*^*Cre/+*^ (*Fgfr1*^*−/f*^*;Fgfr2*^*+/f*^*::Twist2*^*Cre/+*^), *Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ (*Fgfr1*^*+/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^)*,* and *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ embryos were decreased by 7%, 20%, and 55%, respectively, compared to control ([Figure 5A,B,G](#fig5){ref-type="fig"}). Thus, the total number of HCs is decreased in proportion to the decreased length of the cochlea.10.7554/eLife.05921.011Figure 5.Mesenchymal *Fgfr1* and *Fgfr2* regulate the length of the cochlear duct and sensory progenitor proliferation.(**A**, **B**) Phalloidin (**A**) and p75 immunostaining (**B**) of E18.5 whole cochlea showing HCs (phalloidin) and pillar cells (p75) in the cochlear duct of control, *Fgfr1*^*−/f*^*::Twist2*^*Cre/+*^ (*Fgfr1*^*−/f*^*;Fgfr2*^*+/f*^*::Twist2*^*Cre/+*^), *Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ (*Fgfr1*^*+/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^), and *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ embryos. (**C**) Phalloidin (green) staining showing normal HC patterning in the cochlear sensory epithelium. (**D**) Sox2 immunostaining of E14.5 whole cochlea to identify progenitor domains (arrows). (**E**) Sox2 and pHH3 co-immunostaining of E12.5 cochlea sections. (**F**, **G**) Measurement of HC number (**F**) and length of cochleae (**G**) of E18.5 control, *Fgfr1*^*−/f*^*::Twist2*^*Cre/+*^ (*Fgfr1*^*−/f*^*;Fgfr2*^*+/f*^*::Twist2*^*Cre/+*^), *Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ (*Fgfr1*^*+/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^), and *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ embryos. (**H**) Measurement of Sox2^+^ sensory progenitor (green) proliferation (red, pHH3) in E12.5 embryo sections. All samples were compared with controls. \*p \< 0.001. Sample numbers (n) are indicated in data bars. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.011](10.7554/eLife.05921.011)10.7554/eLife.05921.012Figure 5---figure supplement 1.*Twist2*^*Cre*^ targeting of periotic mesenchyme.*Twist2*^*Cre/+*^*;ROSA26*^*lacZ/+*^ (*ROSA*^*lacZ/+*^) double transgenic mice showing βGal activity (xGal, blue) in periotic mesenchymal cells at E9.5 and E10.5. OV, otic vesicle.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.012](10.7554/eLife.05921.012)

To determine whether the effect of loss of mesenchymal FGFRs on cochlear length originates early in development, we examined the size of the Sox2^+^ progenitor domain at the time that HCs commit to differentiate, and cell proliferation within the Sox2^+^ domain before the onset of differentiation. The size of the Sox2^+^ progenitor domain, visualized by whole mount Sox2 staining of E14.5 cochleae was decreased in *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ embryos compared to control embryos ([Figure 5D](#fig5){ref-type="fig"}). In addition, proliferation of Sox2^+^ progenitors from *Fgfr1*^*−/f*^*;Fgfr2*^*−/f*^*::Twist2*^*Cre/+*^ cochleae was significantly (p \< 0.01) decreased compared to control cochleae at E12.5 ([Figure 5E,H](#fig5){ref-type="fig"}). Together, these data show that mesenchymal FGFR signaling is a necessary determinant of cochlear length and sensory progenitor proliferation, but not for cochlear pattern formation or differentiation.

To determine whether the FGF signaling pathway is affected in periotic mesenchyme, whole mount RNA in situ hybridization was used to localize expression of *Etv4* and *Etv5*, two transcription factors that are commonly regulated by FGF signaling ([@bib40]; [@bib14]; [@bib6]; [@bib26]; [@bib52]). Compared to double heterozygous control and *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ inner ears, *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^ inner ears showed decreased expression of *Etv4* and *Etv5* in mesenchyme surrounding the cochlear duct ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}). The only known mesenchymal signaling pathway to regulate sensory progenitor proliferation is a Tbx1/Pou3f4 dependent retinoic acid (RA) signaling cascade ([@bib4], [@bib5][@bib5]). However, *Tbx1* and *Pou3f4* expression, using RNA in situ hybridization in the embryos lacking *Fgf9* and *Fgf20* (*Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^), did not reveal a change in expression of these transcription factors compared to doble heterozygous control and *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ embryos ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}), suggesting that FGF signaling may function independent of RA signaling.

Mesenchymal FGF signal is sufficient to activate sensory progenitor cells proliferation {#s2-6}
---------------------------------------------------------------------------------------

Next we asked whether increased mesenchymal FGFR signaling is sufficient to activate sensory progenitor proliferation. We ectopically expressed a constitutive FGFR1 tyrosine kinase domain in mesenchymal cells by combining the *Twist2*^*Cre*^, *ROSA*^*rtTA*^, and the doxycycline-responsive *TRE-caFgfr1-myc* alleles (*TRE-caFgfr1;ROSA*^*rtTA/+*^*::Twist2*^*Cre/+*^) ([@bib9]). Doxycycline was fed to pregnant female mice beginning at E10.5. Embryos were analyzed at E12.5 for prosensory progenitor proliferation using pHH3 and Sox2 co-immunostaining ([Figure 6A](#fig6){ref-type="fig"}). The proliferation index in control prosensory cells was 2.4 ± 0.5/10,000 μm^2^ ([Figure 6B](#fig6){ref-type="fig"}). However, embryos in which the *caFgfr1-myc* allele was induced in mesenchyme showed a significantly increased (4.1 ± 0.6/10,000 μm^2^, p \< 0.02) proliferation index ([Figure 6B](#fig6){ref-type="fig"}). To test the hypothesis that increased proliferation in sensory progenitors could lead to an increase in cochlear length, *TRE-caFgfr1;ROSA*^*rtTA/+*^*::Twist2*^*Cre/+*^ embryos were induced from E10.5 to E14.5 and cochleae were analyzed at E18.5 ([Figure 6C](#fig6){ref-type="fig"}). Linear densities of IHCs, OHCs, and SCs in *TRE-caFgfr1;ROSA*^*rtTA/+*^*::Twist2*^*Cre/+*^ embryos were comparable (p \> 0.4) to control ([Figure 6E,F](#fig6){ref-type="fig"}). However, the cochlear length in *TRE-caFgfr1;ROSA*^*rtTA/+*^*::Twist2*^*Cre/+*^ embryos was significantly (p \< 0.001) increased by 14% compared to control ([Figure 6D](#fig6){ref-type="fig"}).10.7554/eLife.05921.013Figure 6.Ectopic activation of FGFR signaling in mesenchyme increases sensory progenitor proliferation and cochlear length.(**A**) Sox2 (green) and pHH3 (red) co-immunostaining of E12.5 control and *TRE-caFgfr1;ROSA*^*rtTA/+*^*::Twist2*^*Cre/+*^ embryo sections. (**B**) Measurement of Sox2^+^ sensory progenitor proliferation at E12.5. (**C**) Phalloidin (green) and p75 immunostaining (red) showing the patterning of HCs and pillar cells in the cochlear duct of control and *TRE-caFgfr1;ROSA*^*rtTA/+*^*::Twist2*^*Cre/+*^ embryos. Measurement of the length of the cochleae (**D**), HC number (**E**), and SC number (**F**) of E18.5 control and *TRE-caFgfr1;ROSA*^*rtTA/+*^*::Twist2*^*Cre/+*^ embryos. (**G**) Schematic diagram indicating the requirement for epithelial FGF9/20 signaling to mesenchymal FGFR1/2 to induce sensory progenitor proliferation. \*p \< 0.01 in **B** and \*p \< 0.001 in **D**. Sample numbers (n) are indicated in data bars. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.013](10.7554/eLife.05921.013)10.7554/eLife.05921.014Figure 6---figure supplement 1.*Fgf9* and *Fgf20* regulate the expression of *Etv4* and *Etv5*, but not *Pou3f4* or *Tbx1*.(**A**--**D**) Wholemout mRNA in situ staining of *Etv4* (**A**), *Etv5* (**B**), *Pou3f4* (**C**), and *Tbx1* (**D**) genes on otic vesicles from E11.5 embryos. The genotypes of embryos analyzed are: *Fgf9*^*−/+*^*;Fgf20*^*lacZ/+*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^ and, *Fgf9*^*−/−*^*;Fgf20*^*lacZ/lacZ*^. Images are representative of at least three embryos for each probe and genotype. Scale bar, 500 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.05921.014](10.7554/eLife.05921.014)

Discussion {#s3}
==========

Sensory progenitor proliferation and differentiation are temporally distinct events in cochlear development. In mice, sensory progenitors exit from the cell cycle beginning at the apical end of the cochlea at ∼E12.5 and ending at the base at ∼E14.5. In contrast, differentiation begins in the mid-base at ∼E14.5 and then extends to the base and apex ([@bib48]). Under physiological conditions, once progenitors exit the cell cycle, they do not reenter the cell cycle throughout the life of the organism. Previous studies suggested that during development both epithelial and mesenchymal signals are required to regulate cochlear progenitor proliferation and differentiation ([@bib28]; [@bib12]). However, the mechanisms that control cochlear sensory progenitor proliferation are not known. In this study, we found that epithelial FGF9 and FGF20 signaling to mesenchymal FGFR1 and FGFR2 is required for normal levels of cochlear sensory progenitor proliferation and that inactivation of either the ligands or the mesenchymal receptors results in a shortened cochlea. We also demonstrated that activation of mesenchymal FGFR signaling is sufficient to increase sensory progenitor proliferation and extend cochlear length.

*Fgf9* is expressed in non-sensory epithelia of the cochlea and loss of *Fgf9* results in defects in periotic mesenchymal cell proliferation, causing a hypoplastic otic capsule ([@bib38]). Based on known expression patterns in mesenchyme, *Fgfr1* and *Fgfr2* were considered the most likely targets of FGF9 signaling ([@bib38]). The critical time window for FGF9 signaling was determined to occur before E14.5. By contrast, *Fgf20* is expressed in the sensory epithelium and loss of *Fgf20* results in failure of the lateral compartment of the organ of Corti to fully differentiate ([@bib18]). Based on expression patterns and phenotypic similarities with epithelial *Fgfr1* conditional gene inactivation, FGFR1 was identified as the epithelial target receptor ([@bib37]; [@bib18]).

The effects of epithelial FGFR1 signaling on the length of the cochlear duct exhibit variability among studies. [@bib33] report a 40--50% decrease in cochlear length in *Fgfr1*^*f/f*^*::Six1enh21*^*Cre*^, and *Fgfr1*^*f/f*^::*Emx2*^*Cre*^ conditional knockout mice, by contrast, *Fgf20*^*lacZ/lacZ*^, *Fgf9*^*−/+*^*;Fgf20*^*lacZ/lacZ*^, and *Fgfr1*^*−/f*^*::Foxg1*^*Cre/+*^ mice that we studied ([@bib18], and this study) showed only a 10--25% decrease in cochlear length. It is clear that in both studies defects in epithelial differentiation is likely to result in some decrease in cochlear length. It is also possible that differences in genetic background could contribute to differences in these two studies.

FGF9 and FGF20 are members of the same FGF subfamily and share similar biochemical properties ([@bib51]; [@bib34]). Redundancy between these FGFs has also been demonstrated in kidney development, where both ligands are required for nephron progenitor maintenance ([@bib1]). Interestingly, in both cases, the expression patterns of these two FGFs do not overlap, but nevertheless they appear to signal to a common target tissue, periotic mesenchyme in the developing inner ear and CAP mesenchyme in the developing kidney. For the evolution of the kidney and inner ear, it is possible that additive expression of these FGFs from distinct sources was required to take advantage of their unique receptor specificities or unique interactions with the extracellular matrix.

Tbx1 is a transcription factor that is expressed in both sensory epithelium and mesenchyme ([@bib46]; [@bib39]). Deletion of *Tbx1* in mesenchymal cells resulted in defects in cochlear epithelial proliferation indicating a non-cell autonomous requirement for Tbx1 for cochlear epithelial development ([@bib49]). In addition, the Pou domain containing transcription factor, Pou3f4, also known as Brn4, is expressed in mesenchymal cells in the developing inner ear ([@bib35]). Deletion of *Pou3f4* resulted in reduction of cochlear length and defects in derivatives of the otic mesenchyme including the spiral limbus, scala tympani, and strial fibrocytes ([@bib35]). Furthermore, decreasing gene dosages of *Tbx1* and *Pou3f4* resulted in a significant decrease in sensory epithelial proliferation and cochlear length indicating that Tbx1 and Pou3f4 genetically interact. The RA catabolizing genes *Cyp26a1* and *Cyp26c1*, both targets of Tbx1 and Pou3f4, were decreased in these mice, suggesting that increased RA signaling could directly or indirectly suppress sensory progenitor proliferation ([@bib4], [@bib5][@bib5]). Analysis of *Fgf9* and *Fgf20* double mutant mice showed no change in the expression of Tbx1 and Pou3f4 in mesenchyme surrounding the otic vesicle, suggesting that mesenchymal FGF signaling does not directly affect transcription factors that regulate RA signaling ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}). On the other hand, *Etv4* and *Etv5* function as downstream targets of FGF signaling in other systems including the limb ([@bib26]; [@bib52]), and *Etv4* and *Etv5* expression were decreased in *Fgf9*/*Fgf20* mutant ears. Future studies will be needed to determine whether FGF signaling including ETV4 and ETV5 regulates RA signaling downstream of Tbx1/Pou3f4 or act in parallel to the Tbx1/Pou3f4/RA signaling pathway to regulate sensory progenitor proliferation. Whether the cellular target of RA signaling is in the periotic mesenchyme or the sensory progenitor epithelium also remains to be determined. It is also possible that the number of nearby mesenchymal cells may influence sensory progenitor proliferation. However, considering that loss of *Fgf9* resulted in decreased mesenchymal cell proliferation ([@bib38]) but did not affect HC formation or cochlear length ([Figure 2](#fig2){ref-type="fig"}), alternative mechanisms may need to be considered.

The reactivation of developmental signaling pathways may be important for regeneration. Recent publications showed that inhibition of Notch signaling could induce transdifferentiation of SCs to HCs in a damaged cochlea ([@bib23]; [@bib27]). In addition, Wnt/β-catenin signaling can induce SC proliferation in neonatal mice ([@bib7]; [@bib41]). One intermediate goal of regenerative biology for the inner ear would be to generate large numbers of sensory progenitor cells that could be differentiated into functional HCs and SCs and then be reintroduced into the damaged inner ear. The studies presented here suggest that in efforts to grow inner ear sensory progenitor cells in vitro, that FGF-induced mesenchyme may be necessary. The identification of mesenchymal factors that are regulated by FGF or RA could also be used to support the growth of sensory progenitor cells.

Materials and methods {#s4}
=====================

Generation of *Fgf20*^*Cre*^ mutant mice {#s4-1}
----------------------------------------

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Washington University Division of Comparative Medicine Animal Studies Committee (Protocol Number 20130201). All efforts were made to minimize animal suffering.

*Fgf20*^*Cre*^ knock-in mice were generated using a similar method to that reported previously ([@bib18]). Briefly, exon1 of *Fgf20* was replaced with a Cre-EGFP--FRT-neomycin-FRT cassette to generate *Fgf20*^*Cre(neo)/+*^ mice. The neomycin gene was eliminated by mating with *CAG-FLPe* ([@bib21]) mice to generate *Fgf20*^*Cre/+*^ mice. Genotyping was performed using PCR1: CTGCATTC GCCTCGCCACCCTTGCTACACT; PCR2: GGATCTGCAGGTGGAAGCCGGTGCGGCAGT; PCR3: TTCAGGGTCAGCTTGCCGTAGGTGGCATCG primers, which amplify wild type (335 bp) and mutant (241 bp) PCR fragments. Mice were maintained on a 129X1/SvJ;C57BL/6J mixed background.

Generation of *Fgf9*^*lacZ*^ mutant mice {#s4-2}
----------------------------------------

*Fgf9*^*lacZ*^ mice were derived from International Knockout Mouse Consortium targeted ES cells (project number 24486) ([@bib42]). Chimeric mice derived from injected blastocysts were bred to *Sox2*^*Cre*^ mice ([@bib15]) to remove the nbactP-neo selection cassette and the second exon of the *Fgf9* gene. Genotyping was performed using Wt1: GAAGTCGTGCGTGAGGTGCTCCAGGTCGG; Wt2: CCGCGAATGCTGACCAGGCCCACTGCTAT primers for wild type (172 bp) and mut1: GTT GCA GTGCACGGCAGATACACTTGCTGA; mut2: GCCACTGGTGTGGGCCATAATTCAATTCGC primers for mutant (389 bp) PCR fragments. Mice were maintained on a 129X1/SvJ;C57BL/6J mixed background.

Other mouse lines {#s4-3}
-----------------

*Fgfr1*^*f/f*^, *Fgfr2*^*f/f*^, *Twist2(Dermo1)*^*Cre/+*^, *Foxg1*^*Cre/+*^, *R26R*, *ROSA*^*mTmG/+*^, *TRE-caFgfr1-myc*, *ROSA*^*rtTA/+*^, *Fgf20*^*lacZ/+*^, and *Fgf9*^*−/+*^ mice lines were reported previously ([@bib43]; [@bib17]; [@bib11]; [@bib37]; [@bib44]; [@bib50]; [@bib3]; [@bib31]; [@bib18]; [@bib9]). *Fgfr1*^*−/+*^ and *Fgfr2*^*−/+*^ mice were generated by crossing *Fgfr1*^*f/f*^ and *Fgfr2*^*f/f*^ to *Sox2*^*Cre/+*^ mice, respectively.

βGal staining {#s4-4}
-------------

Embryos were fixed overnight in Mirsky\'s Fixative (National Diagnostics, Atlanta, GA), washed three times in PBT (PBS, 0.1% Tween-20) and incubated in βGal staining solution (2 mM MgCl~2~, 35 mM potassium ferrocyanide, 35 mM potassium ferricyanide, 1 mg/mg X-Gal in PBT) at 37°C until color reaction was apparent. Samples were washed in PBS, fixed in 10% formalin and imaged under a dissecting microscope.

Histology {#s4-5}
---------

For frozen sections, embryos were fixed with 4% paraformaldehyde overnight and washed with PBS. Samples were soaked in 30% sucrose and embedded in OCT compound (Tissue-Tek, Torrance, CA). Samples were sectioned (12 µm) and stored at −80°C for immunohistochemistry.

Quantification of HC and SC numbers {#s4-6}
-----------------------------------

Either phalloidin or Prox1 immunostaining were used to identify HCs and SCs, respectively. To measure the density of HCs and SCs, at least 300 µm regions of the base (10%), middle (40%), and apex (70%) of the cochleae were counted and normalized to 100 µm along the length of the cochlear duct. Inner and OHCs were identified by location and morphology of phalloidin staining. Cell counting was performed using Image J software.

Proliferation and cell death analyses {#s4-7}
-------------------------------------

To analyze progenitor proliferation and cell death, frozen sections were prepared from the entire ventral inner ear of E11.5 or E12.5 embryos. Alternate sections were subjected to staining for pHH3 and Sox2 (for proliferation) or activated-Caspase 3 and Sox2 (for cell death, data not shown). For EdU labeling, pregnant females were injected with 50 µg/g (body weight) of EdU according to the manufacture\'s recommendation. Embryos were collected 2 hr after EdU injection. EdU was detected with the Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen, Carlsbad, CA) according to manufacture\'s instructions. The total area of Sox^+^ cells was measured using Image J software and pHH3^+^ or activated-Caspase 3^+^ cells within the Sox2^+^ domain were counted. Counting was normalized to 10,000 μm^2^ of Sox2^+^ prosensory epithelium.

Immunohistochemistry {#s4-8}
--------------------

For whole mount immunofluorescence, cochleae were isolated and fixed in 4% PFA overnight at 4°C. Samples were washed with PBS and blocked with PBS containing 0.1% triton X-100 and 0.5% donkey serum. Primary antibody was incubated overnight at 4°C. Samples were washed with PBS and incubated with a secondary antibody for 1 hr at room temperature. Samples were washed, placed on a glass microscope slide, coverslipped, and photographed using a Zeiss LSM 700 confocal microscope. For immunofluorescence on histological sections, frozen sections (12 µm) were washed with PBS, blocked with 0.1% triton X-100 and 0.5% donkey serum, and incubated with primary antibodies in a humidified chamber overnight at 4°C. Sections were then washed and incubated with secondary antibody for 1 hr at room temperature. Samples were washed, coverslipped with Vectashield Mounting Media (Vector Labs, Burlingame, CA), and photographed using a Zeiss LSM 700 confocal microscope. Primary antibodies used: Phallodin (R&D Systems, Minneapolis, MN, 1:40), Prox1 (Covance, Princeton, NJ, 1:250), p27 (Neomarkers, Fremont, CA, 1:100), p75 (Chemicon, Billerica, MA, 1:500), β-galactosidase (Abcam, United Kingdom, 1:500), Sox2 (Millipore, Billerica, MA, 1:250, Santa Cruz, Dallas, TX, 1:250), Jag1 (Santa Cruz, Dallas, TX, 1:200), phospho-histone 3 (Sigma--Aldrich, St. Louis, MO, 1:500), and activated Caspase 3 (BD Sciences, San Jose, CA, 1:200).

Statistics {#s4-9}
----------

Numbers of samples are indicated for each experiment. All data are presented as mean ± standard deviation (sd). The p value for difference between two samples was calculated using a two-tailed Student\'s *t*-test or one-way ANOVA where appropriate. p \< 0.05 was considered as significant.
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Thank you for sending your work entitled "Cochlear progenitor number is controlled through mesenchymal FGF receptor signaling" for consideration at *eLife*. Your article has been evaluated by Janet Rossant (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The following individuals responsible for the peer review of your submission have agreed to reveal their identity: Tanya Whitfield (Reviewing editor); Raj Ladher (peer reviewer). A further reviewer remains anonymous.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

As you will see, all three reviewers found the work interesting and potentially important. However, they felt that the data, as they stand, do not provide full support for the proposed model, and that further work and clarification is required. As a minimum, this should include a full characterisation of the mesenchymal phenotype in each of the mutants, including the *Fgf9* and *Fgf20* single mutants for comparison. Improved quantitation of the sensory cell phenotype and levels of proliferation in epithelium and mesenchyme, ideally including a marker other than PHH3, will be important. Alternative interpretations of the mesenchymal phenotype should be considered and discussed. A fuller discussion of the phenotype caused by *Fgfr1* KO in the epithelium is also required, since this also affects cochlear length. The revised version must include citation, acknowledgement and discussion of previously published work that impacts on the current study. In particular, it will be worth examining the IHC phenotype carefully here.

The full reviews are appended below.

Reviewer \#1:

This is an interesting paper that builds on a previous study ([@bib18]) demonstrating a role for *Fgf2*0 in differentiation of the lateral compartment of the cochlea. The new information here is that FGF signalling from epithelium to mesenchyme is both required and sufficient for sensory progenitor proliferation and extension of the cochlear duct. The data are clear and support the conclusions well. However, there is no identification of a potential mechanism for the mesenchymal signal back to the cochlear duct that regulates its growth. As a result, the advance that the study makes over previous work appears to be somewhat incremental.

A few details of the manuscript could be clarified:

The normal expression patterns of *Fgfr*1 and *Fgfr2* in the otic epithelium and periotic mesenchyme at the relevant stages should be presented or referred to early on in the manuscript.

Introduction: '...and that mesenchymal FGF signaling is sufficient to promote...'. This is ambiguous. Is this the same signalling from epithelium to mesenchyme as referred to in the previous sentence, or new signalling from mesenchyme to epithelium, also mediated by FGF?

[Figure 1](#fig1){ref-type="fig"} and Results: Make sure the text follows the order of the panels in the figure and vice versa---i.e. show *Fgf20* first in the figure.

[Figure 1D](#fig1){ref-type="fig"}: The sketch here does not appear to represent the expression patterns shown very well. The two FGF domains appear to abut each other directly, with a very sharp boundary at the junction between non-sensory (thinner) and sensory (thicker) epithelium. This is not shown in the sketch, which does not depict the full extent of the *Fgf20* domain and shows a substantial gap between the two domains.

[Figure 2](#fig2){ref-type="fig"}: It would be helpful to show the *Fgf20*^*-/-*^; *Fgf9*^*+/+*^ phenotype here, to illustrate the effects of the loss of *Fgf20* alone, even though previously published.

In the subsection headed "*Fgf9* and *Fgf20* regulate cochlear length and *Fgf20*, not *Fgf9*, is required for lateral compartment differentiation and patterning", when you state "...the normal pattern of three rows of OHCs... ([Figure 2A, B](#fig2){ref-type="fig"})", there should be a reference to the later panels (C, D) here as well.

[Figure 2C](#fig2){ref-type="fig"}: Please mark on the positions of IHC and OHC on these panels. It looks to me as if there are two rows of IHC in the *Fgf20*^*βGal/βGal*^, especially in the right hand panel. Please comment.

The density of each HC type is measured for several different genotypes. It should be clarified somewhere that where patterning of the organ of Corti is affected, the whole organ is fragmented and that cell measurements are (presumably) taken over patches where the sensory cells are still present. If density was measured along the whole length of the cochlea, presumably IHC density would also be affected.

[Figure 3D](#fig3){ref-type="fig"}: Other areas marked by Jag1, but not highlighted, appear to show significant differences from controls, e.g. in the top left hand corner of the panel, the domain appears to be twice as big as in controls, whereas the stained area towards the bottom of the panel appears much reduced. Please comment.

The Discussion is rather brief, and does not really exploit the detail provided in the Results. In particular, the Discussion does not cover the potential differences in roles between *Fgf9* and *Fgf20*, and *Fgfr1* and *Fgfr2*. My interpretation of the Results was that *Fgf20* primarily signals through *Fgfr1* in the cochlear epithelium to regulate patterning of lateral compartment of the organ of Corti, while *Fgf9* primarily signals through *Fgfr2* in the mesenchyme to regulate cochlear length, with some cross-activity and redundancy between the two FGF pathways. However, the Discussion merely focusses on the redundancy rather than any differences between the two. It would be interesting to relate any differences to the clear differences between the non-overlapping expression domains of each FGF in the developing cochlear duct, and to the expression domains of the FGFRs, which are not shown (see comment above).

In addition, there is no mention of how the mesenchyme may signal back to the epithelium to regulate cochlear growth. It is not made clear in the paragraph about RA signalling whether this is being proposed as the mechanism of mesenchymal to epithelial signalling, but the last sentence of the manuscript appears to indicate that this may be a second signalling pathway that is regulating mesenchymal cell behaviour. Do the authors have any speculation on how the mesenchyme may regulate cochlear duct growth? Are there any candidate factors?

Reviewer \#2:

*Fgfr1* signalling has been implicated in the regulation of the pool of sensory progenitors that give rise to the hair cells and support cells of the mammalian cochlea and in the specification of outer hair cells during later organ of Corti patterning. In previous studies, Huh and colleagues described the role of *Fgf20* in the mediating the latter function. In the current study the authors analyse the role of *Fgf9* and *Fgf20* in the control of the sensory progenitor pool. Using Cre-drivers they suggest that the ligands signal via the mesenchyme and back on to the otic epitehlia.

One of my major criticisms of this paper is the failure to reconcile their data with data that is already published. A recent study of the *Fgfr1* phenotype ([@bib33]) has not been considered and needs to be evaluated in the context of the authors work. For example, in the subsection "Epithelial *Fgfr1* but not *Fgfr2* is required for lateral compartment differentiation", the sentence "however, no quantitative data regarding affected cell types or cochlear length was reported" (in *Foxg1*^*Cre*^ *Fgfr1* mutants) is untrue---the data is presented in Ono et al. Similarly, a paper showing the role of *Fgf20* in the maintenance of Sox2^+^ progenitors (Munnamalai et al., 2012) has not been cited or considered.

With this in mind, it is probably worth highlighting the points that are inconsistent:

a\) In *Fgf9/20* knockouts, *Fgf20*^*Cre*^;*Fgfr1/2* and *Dermo1*^*Cre*^;*Fgfr1/2* mutants the inner hair cells are unaffected. In Ono et al., early deletion (using Six1-Cre and *Foxg1*^*Cre*^) of *Fgfr1* affects IHC; Cochlear length is affected, quite significantly, in the early, epithelial deletions of *Fgfr1* presented by Ono et al. Huh, Warchol and Ornitz do not find any reduction in epithelial size; Proliferation of Sox2^+^ progenitors was unaffected in Ono\'s early deletions of *Fgfr1*.

Alternative interpretations of the mesenchymal requirement of FGFR signalling in the regulation of cochlear length need to be considered. One possibility is that the effect on cochlear length is secondary, not because of a direct action of *Fgf9/20* on *Fgfr1* and *2* in the mesenchyme, but because there is simply less mesenchyme. I think that it is quite likely that a reduction of *Fgfr1* and *2* in the peri-otic mesenchyme at such early stages leads to a reduction in the amount of mesenchyme. As Doetzlhofer et al., had shown, the mesenchyme is important for outgrowth. The authors need to analyse the periotic mesenchyme in these mutants.

The correlation of sensory progenitors with cochlea length is quite a laboured point. It is clear that even in the absence of Sox2^+^ progenitors (see [@bib22]), the cochlea still extends. It is likely that progenitor proliferation plays at best a contributory role.

The cochlear of *Fgf9* nulls, as well as the *Fgf20* nulls and *Fgf9/20* double nulls should also be analysed. Are these the same as wild-types or is the *Fgf9* and *Fgf20* phenotype additive?

Reviewer \#3:

This is an interesting study that attempts to show the relative importance of *Fgf9* and *Fgf20* on the development of the prosensory domain of the mouse cochlea. The control of cell number in the prosensory domain of the cochlea is an important and unresolved issue in the field, as there is no apparent cell death, and so the number of progenitors generated directly affects the size of the organ of Corti.

In the first part of the paper, the authors show a role for *Fgf9* on cochlear length; while *Fgf20* seems to be affecting the number of prosensory progenitors that are being generated, or the way they are being patterned. This role for *Fgf20* has been previously described by this group, and here they extend that work to show that *Fgf9* does not play a role in this aspect. In [Figure 2](#fig2){ref-type="fig"}, the paper suffers from not showing data from *Fgf20*^*-/-*^ mice alone (presumably because this is contained in their earlier publication). I think evidence from this mouse should be included here as part of the current analysis, so that direct comparison is possible; also, its absence makes the description of the various phenotypes rather confusing, and the authors might want to spend some time thinking of a way to describe this part more clearly. In the end of this first section, the authors claim that there are synergistic effects between the two genes; but I am unclear about why they are making this interpretation, since the lack of any patterning defects in *Fgf9*^*-/-*^, seems to suggest that this FGF acts outside the prosensory domain to affect the length of the cochlear duct ([Figure 2](#fig2){ref-type="fig"}).

The main point of the second section ([Figure 3](#fig3){ref-type="fig"}), is that *Fgf9* plays a synergistic role with *Fgf20* in the proliferation of the cells of the prosensory domain that will make up the organ of Corti. This is an interesting observation, but seems to contradict the separate roles that the two genes play as described in [Figure 2](#fig2){ref-type="fig"}, namely prosensory (*Fgf20*) and non-prosensory (*Fgf9*). The data here are also a little difficult. In [Figure 3G and H](#fig3){ref-type="fig"}, they are counting cells in histological sections rather than whole mounts? But it is difficult to know how much of the prosensory domain they actually measure, and did they count in exactly the same basal-apical position? This may have been difficult to do, since the (*Fgf20*^*-/-*^*::Fgf9*^*-/+*^) does show a change in patterning ("less compact"). Thus, the modest counting difference that they observe in [Figure 3G and H](#fig3){ref-type="fig"} could be due to differences in cell distribution within the duct? Indeed, from this figure there does seem to be a trend in their data showing that *Fgf20* has an effect on its own, without *Fgf9*, even if their statistical test does not show a significant difference; and so *Fgf9* could be skewing the data by changing the shape of the duct? This leads me to be skeptical of their interpretation that the genes are acting together, instead of independently on two different elements of the observed phenotype.

[Figure 5](#fig5){ref-type="fig"}: I don\'t think the conclusion that "together, these data show that FGFR1/2, expressed in mesenchymal cells, are required for proper cochlear length formation and for sensory progenitor proliferation, but not for cochlear pattern formation or differentiation" is completely supported in the case of proliferation, since they fail to isolate the two genes for the proliferation part of the study ([Figure 5H](#fig5){ref-type="fig"}), and only look at the double KO. How do we know that FGFR1 is not responsible, on its own, for the proliferation defect, an observation that would be consistent with the previous Pirvola study, I think?

[Figure 6](#fig6){ref-type="fig"}: In which they show that activation of FGFR signalling is sufficient to affect prosensory proliferation, is very interesting, and complements the KO data.

Discussion:

The authors state that their evidence shows that "in this study, we found that epithelial FGF9 and FGF20 signaling to mesenchymal FGFR1 and FGFR2 is required for normal levels of cochlear sensory progenitor proliferation and that inactivation of either the ligands or the mesenchymal receptors results in a shortened cochlea."

Also, that "...the expression patterns of these two FGFs do not overlap, but nevertheless they appear to signal to a common target tissue, periotic mesenchyme in the developing inner ear..."

But how do we know that pro-sensory-derived FGF9 and FGF20 are signaling through mesenchymal FGFR1/2? Why couldn\'t they also be signaling through epithelial FGFRs? The fact that overstimulation of FGFR1/2 in mesenchyme changes the epithelial proliferation may suggest this is one route, but does not prove this, I don\'t think.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled "Cochlear progenitor number is controlled through mesenchymal FGF receptor signaling" for further consideration at *eLife*. Your revised article has been favorably evaluated by Janet Rossant (Senior editor) and Tanya Whitfield (Reviewing editor). The manuscript is much improved and most of the comments have been addressed. There are some discrepancies with previously published work, but these have now been acknowledged and discussed.

A few remaining issues still need to be addressed before acceptance, as outlined below:

1\) As requested, morphological data for the single mutants have been added for comparison in [Figure 2](#fig2){ref-type="fig"}, but no additional *Fgf9*^*-/-*^ single mutant analysis has been added to [Figure 3](#fig3){ref-type="fig"} to show proliferation data for this genotype. Reference is also made to [@bib38], where the authors state that the cochlear duct is of normal length and architecture in *Fgf9*^*-/-*^ mice. However, that paper has no quantitative data concerning proliferation either, and cochlear patterning is not analyzed in detail. If quantitative proliferation data on the single *Fgf9* KO to compare to the double KO are available, they should be included. If they are not available, the claim that the epithelial proliferation phenotype in the double mutant reflects a synergy between the two Fgfs should perhaps be toned down.

2\) None of the data shown appear to use simple pairwise comparisons. Each graph usually shows one (or more) control situation and several experimental situations (e.g. [Figure 3H](#fig3){ref-type="fig"}: one control and two experiments to which a statistical test is applied). If each experiment is compared with the same control, this is not a pairwise comparison, and ANOVA with multiple sample correction should be used. In any case, when an asterisk is used on the bar graphs, it should be clarified what is being compared with what, either with a description in the legend or by using a horizontal bar between the relevant control and the experimental case (e.g. [Figure 2](#fig2){ref-type="fig"}: are all samples being compared with the left hand (white) double heterozygote control?).

10.7554/eLife.05921.016

Author response

*As you will see, all three reviewers found the work interesting and potentially important. However, they felt that the data, as they stand, do not provide full support for the proposed model, and that further work and clarification is required. As a minimum, this should include a full characterisation of the mesenchymal phenotype in each of the mutants, including the* Fgf9 *and* Fgf20 *single mutants for comparison*.

We have added *Fgf9* and *Fgf20* single mutant data to [Figure 2](#fig2){ref-type="fig"}. The new data include representative images and quantitation of HC and SC numbers and cochlear length at E18.5.

*Improved quantitation of the sensory cell phenotype and levels of proliferation in epithelium and mesenchyme, ideally including a marker other than PHH3, will be important*.

We have labeled embryos with EdU at E11.5 and quantified cell proliferation in the Sox2^+^ domain. The genotypes analyzed include: *Fgf9*^*-/+*^;*Fgf20*βGal*/+*; *Fgf9*^*-/+*^*;Fgf20*βGal/βGal; *Fgf9*^*-/-*^;*Fgf20*βGal/βGal. These data are consistent with our previous data in [Figure 3E](#fig3){ref-type="fig"} showing reduced epithelial proliferation in the double mutant mouse embryo cochlear duct. The data is shown in [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}.

*Alternative interpretations of the mesenchymal phenotype should be considered and discussed*.

We have added to the Discussion additional interpretations of the mesenchymal phenotype.

*A fuller discussion of the phenotype caused by* Fgfr1 *KO in the epithelium is also required, since this also affects cochlear length*.

We have added to the Discussion additional comparisons of the epithelial phenotype to the phenotype seen in mice conditionally lacking FGFR1, published by the Ono et al.

*The revised version must include citation, acknowledgement and discussion of previously published work that impacts on the current study. In particular, it will be worth examining the IHC phenotype carefully here*.

We have added additional citations and acknowledgements as requested. In the genetic background used in our experiments we do not see any effects on IHC differentiation. The total number of IHCs is decreased in the *Fgf9/20* double knockout embryos and in the mesenchymal FGFR conditional knockouts in which the length of the cochlea is dramatically shortened. These points are now discussed in the revised manuscript.

*The full reviews are appended below*.

Reviewer \#1:

*This is an interesting paper that builds on a previous study (*[@bib18]*) demonstrating a role for* Fgf20 *in differentiation of the lateral compartment of the cochlea. The new information here is that FGF signalling from epithelium to mesenchyme is both required and sufficient for sensory progenitor proliferation and extension of the cochlear duct. The data are clear and support the conclusions well. However, there is no identification of a potential mechanism for the mesenchymal signal back to the cochlear duct that regulates its growth. As a result, the advance that the study makes over previous work appears to be somewhat incremental*.

We agree with the reviewers that we have not identified the mesenchymal signal back to the cochlear duct that regulates its growth. However, we have ruled out several candidate pathways. What we have done is identify that mesenchymal FGFR signaling, possibly through activation of *Etv4/5*, is a critical pathway that will regulate the putative mesenchymal signal back to the cochlear duct. This is an important key step in understanding the ultimate, and currently elusive, molecular mechanism that regulates cochlear progenitor cell growth.

*A few details of the manuscript could be clarified*:

*The normal expression patterns of* Fgfr1 *and* Fgfr2 *in the otic epithelium and periotic mesenchyme at the relevant stages should be presented or referred to early on in the manuscript.*

We have cited two references, for the *Fgfr1* and *Fgfr2* expression patterns in the otic epithelium and periotic mesenchyme at early, E10-12, stages of development. (Pirvola et al. J. Neuroscience 2000 and Neuron 2002).

Introduction: '...and that mesenchymal FGF signaling is sufficient to promote...'. This is ambiguous. Is this the same signalling from epithelium to mesenchyme as referred to in the previous sentence, or new signalling from mesenchyme to epithelium, also mediated by FGF?

We have clarified this stated conclusion by indicating that *Fgf9* and FGF20 signal to mesenchymal FGFRs and that mesenchymal FGFR signaling is necessary and sufficient to regulate cochlear progenitor cell number.

[*Figure 1*](#fig1){ref-type="fig"} *and Results: Make sure the text follows the order of the panels in the figure and vice versa---i.e. show* Fgf20 *first in the figure*.

We have modified the text to follow the order of the figure.

[*Figure 1D*](#fig1){ref-type="fig"}*: The sketch here does not appear to represent the expression patterns shown very well. The two FGF domains appear to abut each other directly, with a very sharp boundary at the junction between non-sensory (thinner) and sensory (thicker) epithelium. This is not shown in the sketch, which does not depict the full extent of the* Fgf20 *domain and shows a substantial gap between the two domains*.

We have redrawn the sketch to better reflect the expression patterns shown in the immunostained sections.

[*Figure 2*](#fig2){ref-type="fig"}*: It would be helpful to show the* Fgf20^-/-^; Fgf9^+/+^ *phenotype here, to illustrate the effects of the loss of* Fgf20 *alone, even though previously published*.

We have added the *Fgf9*^*-/-*^;*Fgf20*^*+/+*^ and *Fgf9*^*+/+*^;*Fgf20*^*-/-*^ genotypes in [Figure 2](#fig2){ref-type="fig"} as requested. The *Fgf9*^*-/-*^;*Fgf20*^*+/+*^ genotype is comparable to the double heterozygous control and *Fgf9*^*-/-*^;*Fgf20*^*-/+*^ genotypes. The *Fgf9*^*+/+*^;*Fgf20*^*-/-*^ genotype is comparable to *Fgf9*^*-/+*^;*Fgf20*^*-/-*^ genotype. These data indicate that there is no cochlear patterning phenotype resulting from loss of *Fgf9* as long as one wild type allele of *Fgf20* is present. Furthermore, loss of one copy of *Fgf9* does not contribute to either outer hair cell loss or cochlear length shortening.

*In the subsection headed "*Fgf9 *and* Fgf20 *regulate cochlear length and* Fgf20*, not* Fgf9*, is required for lateral compartment differentiation and patterning", when you state "...the normal pattern of three rows of OHCs... (*[*Figure 2A, B*](#fig2){ref-type="fig"}*)", there should be a reference to the later panels (C, D) here as well*.

We added reference to panels C and D as suggested.

[*Figure 2C*](#fig2){ref-type="fig"}*: Please mark on the positions of IHC and OHC on these panels. It looks to me as if there are two rows of IHC in the* Fgf20^βGal/βGal^*, especially in the right hand panel. Please comment*.

We have marked IHC and OHC as suggested. Yes, there are two rows of IHC in the sensory epithelial clumps. This was previously reported by us.

*The density of each HC type is measured for several different genotypes. It should be clarified somewhere that where patterning of the organ of Corti is affected, the whole organ is fragmented and that cell measurements are (presumably) taken over patches where the sensory cells are still present. If density was measured along the whole length of the cochlea, presumably IHC density would also be affected*.

We counted three regions of each cochlea (at 10%, 40%, and 70% along the length). In total, more than 900µm of each cochlea was counted. Due to delayed hair cell differentiation in *Fgf20*^*-/-*^ compound mutants, we counted only the regions that contained differentiated sensory cells. Two rows of IHC are present in patch regions and no IHCs were detected in the region between the sensory patches. Therefore, IHC density was not changed throughout the cochlea. We explained this in the Methods section.

[*Figure 3D*](#fig3){ref-type="fig"}*: Other areas marked by Jag1, but not highlighted, appear to show significant differences from controls, e.g. in the top left hand corner of the panel, the domain appears to be twice as big as in controls, whereas the stained area towards the bottom of the panel appears much reduced. Please comment*.

At E14.5, *Fgf9*^*-/-*^;*Fgf20*^*-/-*^ embryos had very shortened cochlear length compared to other genotypes. Therefore the angle of the cochlear turns in these embryos do not match that of other genotypes. The regions of Jag1 staining that are not boxed are sectioned at an oblique angle and thus cannot be compared. The boxed regions are examples of sections that perpendicularly transect the cochlear duct and thus can be compared across genotypes. This has been clarified in the figure legend.

*The Discussion is rather brief, and does not really exploit the detail provided in the Results. In particular, the Discussion does not cover the potential differences in roles between* Fgf9 *and* Fgf20*, and* Fgfr1 *and* Fgfr2*. My interpretation of the Results was that* Fgf20 *primarily signals through* Fgfr1 *in the cochlear epithelium to regulate patterning of lateral compartment of the organ of Corti, while* Fgf9 *primarily signals through* Fgfr2 *in the mesenchyme to regulate cochlear length, with some cross-activity and redundancy between the two FGF pathways. However, the Discussion merely focusses on the redundancy rather than any differences between the two. It would be interesting to relate any differences to the clear differences between the non-overlapping expression domains of each FGG in the developing cochlear duct, and to the expression domains of the FGFRs, which are not shown (see comment above)*.

We have included discussion regarding specific roles of *Fgf9* and *Fgf20* and their receptors as shown below (extracted from the Discussion section):

*"Fgf9* is expressed in non-sensory epithelia of the cochlea and loss of *Fgf9* results in defects in periotic mesenchymal cell proliferation \[...\] FGFR1 was identified as the epithelial target receptor ([@bib18]; [@bib37])."

*In addition, there is no mention of how the mesenchyme may signal back to the epithelium to regulate cochlear growth. It is not made clear in the paragraph about RA signalling whether this is being proposed as the mechanism of mesenchymal to epithelial signalling, but the last sentence of the manuscript appears to indicate that this may be a second signalling pathway that is regulating mesenchymal cell behaviour*. *Do the authors have any speculation on how the mesenchyme may regulate cochlear duct growth? Are there any candidate factors?*

At present *Tbx1/Pou3f4* induction of RA signaling is the only known mesenchymal factor to induce sensory progenitor proliferation. We showed that *Tbx1* and *Pou3f4* were not changed in *Fgf9*/*Fgf20* mutant inner ear. However, we found that *Etv4* and *Etv5* were decreased in *Fgf9*/*Fgf20* mutant inner ear. We speculate that downstream targets of *Etv4* and *Etv5* might induce sensory epithelial proliferation. We described these possibilities in the Discussion.

Reviewer \#2:

*One of my major criticisms of this paper is the failure to reconcile their data with data that is already published. A recent study of the* Fgfr1 *phenotype (*[@bib33]*) has not been considered and needs to be evaluated in the context of the authors work. For example, in the subsection "Epithelial* Fgfr1 *but not* Fgfr2 *is required for lateral compartment differentiation", the sentence "however, no quantitative data regarding affected cell types or cochlear length was reported" (in* Foxg1^Cre^ Fgfr1 *mutants) is untrue---the data is presented in Ono et al. Similarly, a paper showing the role of* Fgf20 *in the maintenance of Sox2*^*+*^ *progenitors (Munnamalai et al., 2012) has not been cited or considered*.

*With this in mind, it is probably worth highlighting the points that are inconsistent*:

*In* Fgf9/20 *knockouts,* Fgf20^Cre^;Fgfr1/2 *and* Dermo1^Cre^;Fgfr1/2 *mutants the inner hair cells are unaffected. In Ono et al., early deletion (using* Six1-Cre and Foxg1^Cre^*) of* Fgfr1 *affects IHC*;

We agree with the reviewer in that there are differences in the observed phenotypes between data shown here and that shown by [@bib33]. We have modified the Results section to include the Ono et al. observations. In the Discussion, we attempt to reconcile these differences in phenotype. We think that the differences are most likely attributed to differences in genetic background, although the genetic background of the Ono et al. mice were not reported.

*Cochlear length is affected, quite significantly, in the early, epithelial deletions of* Fgfr1 *presented by Ono et al. Huh, Warchol and Ornitz do not find any reduction in epithelial size*;

We observed a 10-25% decrease of cochlear length in *Foxg1*^*Cre*^, *Fgfr1*^*-/f*^ mutants, which is comparable with what we observed in *Fgf20*^*-/-*^ mutants. We maintain our mouse lines on a 129X1/SvJ;C57BL/6J mixed background. We observed a shorter cochlear length in *Fgf20* mutant when on a pure C57BL/6J genetic background (not shown). We speculate that the difference between what we observed and Ono et al. may due to different genetic backgrounds.

*Proliferation of Sox2*^*+*^ *progenitors was unaffected in Ono\'s early deletions of* Fgfr1*.*

We observed that progenitor proliferation was decreased only with mesenchymal FGFR deletion (with *Dermo1*^*Cre*^) but not with epithelial FGFR deletion (with *foxg1*^*Cre*^ or *Fgf20*^*Cre*^). This result is consistent with the observations of Ono et al.

*Alternative interpretations of the mesenchymal requirement of FGFR signalling in the regulation of cochlear length need to be considered. One possibility is that the effect on cochlear length is secondary, not because of a direct action of* Fgf9/20 *on* Fgfr1 *and* 2 *in the mesenchyme, but because there is simply less mesenchyme. I think that it is quite likely that a reduction of* Fgfr1 *and* 2 *in the peri-otic mesenchyme at such early stages leads to a reduction in the amount of mesenchyme. As Doetzlhofer et al., had shown, the mesenchyme is important for outgrowth. The authors need to analyse the periotic mesenchyme in these mutants*.

Out data is consistent with the observations of Montcouquiol 2003 and Doetzlhofer 2004 showing that mesenchyme is important for epithelial progenitor growth, presumably through production of some trophic factor. Pirvola, 2004 showed that periotic mesenchyme proliferation was decreased in *Fgf9* mutant, resulting in a hypoplastic otic capsule. But this did not affect either cochlear length or progenitor proliferation ([@bib38]). Therefore, decreased mesenchymal cell number is unlikely to be the direct cause of the epithelial phenotype. Rather, we propose that FGF signaling within mesenchyme affects some factor that signals reciprocally to epithelial progenitors. We have analyzed periotic mesenchyme for candidate signaling molecules and targets of FGFR signaling. We have shown that *Etv4* is decreased, but we have not yet found a mesenchymal-derived signaling molecule that could regulate epithelial proliferation.

*The correlation of sensory progenitors with cochlea length is quite a laboured point. It is clear that even in the absence of Sox2*^*+*^ *progenitors (see* [@bib22]*), the cochlea still extends. It is likely that progenitor proliferation plays at best a contributory role*.

We agree with the reviewer. For cochlea to elongate, at least two mechanisms are required, 1) Cochlear length should depend on the total number of available differentiated hair cells (which depend on total numbers of progenitor cells); 2) Cochlear length should depend on the proper organization of sensory cells into one row of IHC and 3 rows of OHCs, governed by convergent extension. Many PCP mutants that have disrupted convergent extension show decreased cochlear length. We posit that *Fgf9/20* signaling to mesenchyme is required for progenitor proliferation, thus affecting cochlear length. In addition, FGF20 signaling to epithelial FGFR1 regulates sensory cell differentiation and this also affects cochlear length, but, in our mouse genetic background, this is a relatively small effect (10-25%).

*The cochlear of* Fgf9 *nulls, as well as the* Fgf20 *nulls and* Fgf9/20 *double nulls should also be analysed. Are these the same as wild-types or is the* Fgf9 *and* Fgf20 *phenotype additive?*

We have added these data to [Figure 2](#fig2){ref-type="fig"}. *Fgf9*^*-/-*^ or *Fgf9*^*-/-*^;*Fgf20*^*-/+*^ does not affect cochlear length and HC/SC number. In addition, *Fgf20*^*-/-*^ and *Fgf9*^*-/+*^;*Fgf20*^*-/-*^ showed a similar phenotype.

Reviewer \#3:

*In the first part of the paper, the authors show a role for* Fgf9 *on cochlear length; while* Fgf20 *seems to be affecting the number of prosensory progenitors that are being generated, or the way they are being patterned. This role for* Fgf20 *has been previously described by this group, and here they extend that work to show that* Fgf9 *does not play a role in this aspect. In* [*Figure 2*](#fig2){ref-type="fig"}*, the paper suffers from not showing data from* Fgf20^-/-^ *mice alone (presumably because this is contained in their earlier publication). I think evidence from this mouse should be included here as part of the current analysis, so that direct comparison is possible; also, its absence makes the description of the various phenotypes rather confusing, and the authors might want to spend some time thinking of a way to describe this part more clearly*.

We have added the *Fgf9*^*-/-*^ and *Fgf20*^*-/-*^ data to [Figure 2](#fig2){ref-type="fig"}. See response to reviewer 2 above.

*In the end of this first section, the authors claim that there are synergistic effects between the two genes; but I am unclear about why they are making this interpretation, since the lack of any patterning defects in* Fgf9^-/*-*^*, seems to suggest that this FGF acts outside the prosensory domain to affect the length of the cochlear duct (*[*Figure 2*](#fig2){ref-type="fig"}*)*.

We agree with the reviewer that FGF9 acts outside of the prosensory domain to affect the length of cochlear duct. Our data shows that FGF20 also acts outside of the prosensory domain to affect the length of cochlear duct and functions together with FGF9. Receptor inactivation in mesenchyme strongly suggests that the target of FGF9 and FGF20 is periotic mesenchyme. Our conclusion is that there is synergism in signaling to mesenchyme, but no synergism in signaling to epithelium.

*The main point of the second section (*[*Figure 3*](#fig3){ref-type="fig"}*), is that* Fgf9 *plays a synergistic role with* Fgf20 *in the proliferation of the cells of the prosensory domain that will make up the organ of Corti. This is an interesting observation, but seems to contradict the separate roles that the two genes play as described in* [*Figure 2*](#fig2){ref-type="fig"}*, namely prosensory (*Fgf20*) and non-prosensory (*Fgf9*)*.

The reviewer has astutely identified the key observation of this work. In [Figure 2](#fig2){ref-type="fig"} the phenotype is observed at E18.5. We are hypothesizing, based on the data shown, that the FGF9/20 double knockout encompasses two phenotypes that are developmentally distinct and separable. 1) A patterning phenotype that is due to FGF20 signaling to epithelial FGFR1 as was described in our previous publication (Huh, 2012). This patterning phenotype is independent of FGF9. 2) A cochlear length phenotype that demonstrates synergism between FGF9 and FGF20. [Figure 3](#fig3){ref-type="fig"} begins to define how these two phenotypes differ. The key data is in [Figure 3A](#fig3){ref-type="fig"}. This shows that Control or FGF20 knockout cochlea have normal numbers of sensory progenitor cells. In contrast the *Fgf9/20* double knockout has significantly reduced numbers of progenitor cells. From these data we conclude that FGF20 alone does not affect progenitor cell number, but rather functions later in development to regulate epithelial patterning (differentiation). In contrast FGF9/20 together regulate progenitor cell number. Therefore, these are really not contradictory results and actually define two distinct developmental processes.

*The data here are also a little difficult. In* [*Figure 3G and H*](#fig3){ref-type="fig"}*, they are counting cells in histological sections rather than whole mounts? But it is difficult to know how much of the prosensory domain they actually measure, and did they count in exactly the same basal-apical position? This may have been difficult to do, since the (*Fgf20^-/-^::Fgf9^-/+^) *does show a change in patterning ("less compact"). Thus, the modest counting difference that they observe in* [*Figure 3G and H*](#fig3){ref-type="fig"} *could be due to differences in cell distribution within the duct? Indeed, from this figure there does seem to be a trend in their data showing that* Fgf20 *has an effect on its own, without* Fgf9*, even if their statistical test does not show a significant difference; and so* Fgf9 *could be skewing the data by changing the shape of the duct? This leads me to be skeptical of their interpretation that the genes are acting together, instead of independently on two different elements of the observed phenotype*.

We counted pHH3^+^ cells within the Sox2^+^ sensory progenitor domain throughout the entire cochlear duct, counting every second section from base to apex. In the revised manuscript, we have repeated this analysis for the E11.5 time point using EdU labeling. The result was consistent with the data in [Figure 3G and H and is](#fig3){ref-type="fig"} shown in [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}.

[*Figure 5*](#fig5){ref-type="fig"}*: I don\'t think the conclusion that "together, these data show that FGFR1/2, expressed in mesenchymal cells, are required for proper cochlear length formation and for sensory progenitor proliferation, but not for cochlear pattern formation or differentiation" is completely supported in the case of proliferation, since they fail to isolate the two genes for the proliferation part of the study (*[*Figure 5H*](#fig5){ref-type="fig"}*), and only look at the double KO. How do we know that FGFR1 is not responsible*, *on its own, for the proliferation defect, an observation that would be consistent with the previous Pirvola study, I think?*

The reviewer is correct. We have reworded the paragraph to state that mesenchymal FGFR signaling is a necessary determinant of cochlear length and sensory progenitor proliferation, but not for cochlear pattern formation or differentiation.

The Pirvola study inactivated epithelial *Fgfr1* but did not measure proliferation or effects on cochlear length. We repeated this experiment and showed that there is no effect on sensory progenitor proliferation ([Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}) and a very small effect on cochlear length (9%).

[*Figure 6*](#fig6){ref-type="fig"}*: In which they show that activation of FGFR signalling is sufficient to affect prosensory proliferation, is very interesting, and complements the KO data*.

*Discussion*:

*The authors state that their evidence shows that "in this study, we found that epithelial FGF9 and FGF20 signaling to mesenchymal FGFR1 and FGFR2 is required for normal levels of cochlear sensory progenitor proliferation and that inactivation of either the ligands or the mesenchymal receptors results in a shortened cochlea*.*"*

*Also, that "...the expression patterns of these two FGFs do not overlap*, *but nevertheless they appear to signal to a common target tissue, periotic mesenchyme in the developing inner ear..."*

*But how do we know that pro-sensory-derived FGF9 and FGF20 are signaling through mesenchymal FGFR1/2? Why couldn\'t they also be signaling through epithelial FGFRs? The fact that overstimulation of FGFR1/2 in mesenchyme changes the epithelial proliferation may suggest this is one route, but does not prove this, I don\'t think*.

We posit that FGF9/20 are unlikely to signal to epithelial FGFRs to regulate progenitor cell proliferation based on phenotypic comparisons of the different tissue-specific receptor knockouts. Epithelial deletion of *Fgfr1/2* did not show a dramatic decrease in cochlear length or progenitor proliferation compared to *Fgf9/20* deletion. On the other hand, mesenchymal deletion of *Fgfr1/2* showed a severe decrease of cochlear length and progenitor proliferation, which was comparable to the *Fgf9/20* mutant, but no patterning phenotype. We believe that these data demonstrate that mesenchymal *Fgfr1/2* are required for proper cochlear length formation and that this phenotype likely results from reduced progenitor proliferation and fewer progenitor cells. We have elaborated on this in the Discussion.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*1) As requested, morphological data for the single mutants have been added for comparison in* [*Figure 2*](#fig2){ref-type="fig"}*, but no additional* Fgf9^-/-^ *single mutant analysis has been added to* [*Figure 3*](#fig3){ref-type="fig"} *to show proliferation data for this genotype. Reference is also made to* [@bib38]*, where the authors state that the cochlear duct is of normal length and architecture in* Fgf9^-/-^ *mice. However, that paper has no quantitative data concerning proliferation either, and cochlear patterning is not analyzed in detail. If quantitative proliferation data on the single* Fgf9 *KO to compare to the double KO are available, they should be included. If they are not available, the claim that the epithelial proliferation phenotype in the double mutant reflects a synergy between the two Fgfs should perhaps be toned down.*

We have not measured proliferation in *Fgf9*^*-/-*^ embryos because we have not observed any phenotype that affects hair or supporting cell number or overall length of the cochlear duct in these mice. If the editors or reviewers require these data we can add it, but this will require 3-4 weeks to time mate and analyze the appropriate mice.

We have modified the text to say that comparison of cochlear epithelial cell proliferation was compared to double heterozygous controls.

We do not use the word synergy, but we do state that FGF9 and FGF20 have redundant function. This is based on the lack of a cochlear phenotype in *Fgf9*^*-/-*^ embryos and the appearance of a sensory epithelial proliferation phenotype in the *Fgf9/20* double mutant that is not observed in *Fgf20*^*-/-*^ cochleae.

*2) None of the data shown appear to use simple pairwise comparisons. Each graph usually shows one (or more) control situation and several experimental situations (e.g.* [*Figure 3H*](#fig3){ref-type="fig"}*: one control and two experiments to which a statistical test is applied). If each experiment is compared with the same control, this is not a pairwise comparison, and ANOVA with multiple sample correction should be used. In any case, when an asterisk is used on the bar graphs, it should be clarified what is being compared with what, either with a description in the legend or by using a horizontal bar between the relevant control and the experimental case (e.g.* [*Figure 2*](#fig2){ref-type="fig"}*: are all samples being compared with the left hand (white) double heterozygote control?)*.

We have clarified the statistical comparisons to state that two-way comparisons used Student's t test and we used one-way ANOVA for comparison of more than three samples.
